Paving the way for liquid biopsy

Cancer Liquid Biopsy

A minimally invasive method of testing for biomarkers of cancer and other diseases, liquid biopsy can sidestep costly and stressful surgical procedures. All you need are blood or other body fluid samples and sensitive and specific solutions to detect and analyze circulating cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), cell-free miRNA, cancer exosomes and circulating tumor cells (CTCs). QIAGEN offers robust, efficient and streamlined solutions to empower your research through liquid biopsy. From collection through analysis, our solutions help to standardize your processes and advance biomarker discovery for early detection, monitoring or guided treatment with precision medicine.

Get an overview of our dedicated solutions

Recognizing trends in cancer research can help to accelerate our knowledge and push the field forward. Share your opinion on hot topics and see the results with our live polls. Look out for them on our community pages and let us know if you have an idea for a new poll.

Cell-free DNA from blood

Cancer Insights Session: Multianalyte Studies of Liquid Biopsies

Working with cell-free DNA, extracellular vesicles or CTCs? Have you ever asked yourself:

• Do we miss (or even waste) genomic and transcriptomic information by considering only one analyte?
• How would the picture change if all analytes could be investigated from the same sample?

Featured webinar:

QIAseq Targeted Methyl Panels – A liquid biopsy-compatible solution for detection of methyl markers in NGS

The analysis of tumor-associated differential cell-free DNA methylation has emerged as a promising biomarker for early detection, prognosis and real-time follow-up of tumor dynamics. Brian Dugan, QIAGEN, introduces new QIAseq Targeted Methyl Panels which deliver a novel, highly sensitive solution to determine methylation status from the most challenging sample types.